NEXGEL Appoints Dr. Leonard Nelson and Dr. Neil Chesen to Scientific Advisory Board
September 29 2022 - 7:30AM
NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a
leading provider of ultra-gentle, high-water-content hydrogel
products for healthcare and consumer applications, announced today
that the Company has appointed Dr. Neil Chesen and Dr. Leonard
Nelson to its Scientific Advisory Board.
Dr. Nelson serves as Co-Director of the
pediatric ophthalmology department and Director of the Strabismus
Center at Wills Eye Hospital. He is an associate professor of
ophthalmology and pediatrics at Thomas Jefferson University’s
Sidney Kimmel Medical College and staff member at Thomas Jefferson
University Hospital, Lankenau Medical Center and Children’s
Hospital of Philadelphia. Dr. Nelson previously served on staff at
St. Christopher's Hospital for Children.
He earned a Doctor of Medicine degree from
Harvard Medical School, as well as completed his surgical
internship at New England Deaconess Hospital and ophthalmology
residency at New York University, Bellevue Hospital Center. He went
on to complete a fellowship in pediatric ophthalmology at the
Children’s National Hospital of GW University Hospital and
fellowship in ocular genetics at the Wilmer Eye Institute of Johns
Hopkins Medicine. Additionally, Dr. Nelson obtained his Master of
Business Administration degree at St. Joseph’s University and
bachelor’s degree in biology from Columbia University. He is the
co-editor of the Journal of Pediatric Ophthalmology and Strabismus
and authored over 300 publications and 15 textbooks in pediatric
ophthalmology. He belongs to the American Association for Pediatric
Ophthalmology and Strabismus and American Academy of Ophthalmology,
among others.
“The NEXGEL team is constantly working to
advance its mission of creating high-quality hydrogel products that
can be worn by both consumers and patients for long periods of time
with zero irritation,” said Dr. Nelson. “I look forward to joining
the Scientific Advisory Board to further NEXGEL’s pursuit in
developing these novel solutions for new indications.”
In addition to Dr. Nelson, Dr. Chesen is a
board-certified ophthalmologist who has been in private practice at
Chesen Laser Eye Center for 33 years, with extensive experience in
cataract and LASIK procedures. He is also board-certified in
internal medicine – one of only 40 physicians in the U.S. with this
double board certification. Dr. Chesen received his bachelor’s
degree in biology from Lafayette College and Doctor of Medicine
degree from Jefferson Medical College. He completed his residency
in internal medicine at Einstein Medical Center in Philadelphia and
residency in ophthalmology at Nassau University Medical Center in
East Meadow, N.Y. Dr. Chesen has hospital privileges at the Reading
Hospital – Tower Health, Penn State Health St. Joseph Medical
Center, where he is chairman of the department of ophthalmology,
and Surgical Institute of Reading, where he currently serves as
Board Chairman. He is a member of the American Academy of
Ophthalmology.
“NEXGEL’s high-water content hydrogel technology
is extremely unique in that it is ultra-gentle on the skin and has
numerous product applications across the entire healthcare
landscape,” added Dr. Chesen. “Through my decades of experience as
an ophthalmologist, I see a lot of potential in these hydrogels for
medicinal purposes, as well as the many others that NEXGEL
currently has in its pipeline.”
“As Drs. Chesen and Nelson are well-known
leaders in the field of ophthalmology, NEXGEL will greatly benefit
from their extensive medical knowledge and expertise as we continue
to develop solutions using our hydrogels to help different kinds of
patients around the U.S. and world,” concluded Adam Levy, NEXGEL
CEO.
About NEXGEL, INC.NEXGEL is a
leading provider of ultra-gentle, high-water-content hydrogels for
healthcare and consumer applications. Based in Langhorne, Pa., the
Company has developed and manufactured electron-beam, cross-linked
hydrogels for over two decades. Alongside its strategic partners,
NEXGEL has formulated more than 200 different combinations to bring
natural ingredients to gentle skin patches that can be worn for
long periods of time with little to no irritation.
Investor Contact:Valter Pinto,
Managing DirectorKCSA Strategic
Communications212.896.1254valter@kcsa.com
Media Contacts:Raquel Cona /
Michaela FawcettKCSA Strategic Communications212.896.1204 /
978.995.4683rcona@kcsa.com / mfawcett@kcsa.com
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From Apr 2023 to Apr 2024